Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANT: Lanreotide and Temozolomide in Thoracic Neuroendocrine Tumors
NCT02698410Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jul 2016
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in thoracic neuroendocrine tumor, sponsored by Ipsen. Primary endpoint: Disease Control Rate at 9 months. Started Jul 2016; status: completed.
02
Drugs
lanreotide
03
Conditions
thoracic neuroendocrine tumor
Beyond the preview
Go deeper on NCT02698410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698410.